ISPOR - PDG16 PREDICTING THE COST-EFFECTIVENESS OF GENERIC VERSUS BRAND DABIGATRAN USING PHARMACOMETRIC ESTIMATES AMONG PATIENTS WITH ATRIAL FIBRILLATION

Full Text

PDG16 PREDICTING THE COST-EFFECTIVENESS OF GENERIC VERSUS BRAND DABIGATRAN USING PHARMACOMETRIC ESTIMATES AMONG PATIENTS WITH ATRIAL FIBRILLATION

Abstract

Authors

C.Y. Wang S. Kim K. Lingineni S. Schmidt K. Diaby J. Brown

Back to Volume 22, Supplemental S2

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now